Grifols' GigaGen Receives FDA Clearance Of IND Application For Phase 1 Trial Of Recombinant Polyclonal For HBV Treatment, GIGA-2339
Portfolio Pulse from Benzinga Newsdesk
GigaGen, a subsidiary of Grifols, has received FDA clearance for its IND application to initiate a Phase 1 trial for GIGA-2339, a recombinant polyclonal therapeutic aimed at treating chronic hepatitis B virus (HBV) infection. The trial is expected to start in Q4 2024.
July 31, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Grifols' subsidiary GigaGen has received FDA clearance for a Phase 1 trial of GIGA-2339, a new recombinant polyclonal therapeutic for HBV treatment. This marks a significant step in Grifols' innovation strategy.
The FDA clearance for the Phase 1 trial of GIGA-2339 is a significant milestone for Grifols, indicating progress in their innovation strategy and potential future revenue from a new therapeutic. This positive regulatory news is likely to boost investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100